 |
Sard Verbinnen & Co. represents Premier Biotech, which today received emergency use authorization from the US Food & Drug Administration to distribute a COVID-19 antibodies test manufactured by China's Hangzhou Biotest Biotech. The product produces results in 10 minutes.
Todd Bailey, Premier CEO called the FDA's decision "great news for communities across the U.S. that continue to struggle to access adequate COVID-19 testing, which healthcare experts agree is essential to successful recovery from the COVID-19 crisis."
The emergency use authorization confirms the National Cancer Institute's research that found the product exceeds the 95% specificity and 90% sensitivity standards set by the FDA.
Bailey said Premier would continue to follow regulatory guidelines closely as it distributes the test kit for emergency use to authorized laboratories through the US.
Sard Verbinnen's Lindsay Charles represents Minneapolis-based Premier Biotech.
Jim Weiss, founder & chairman of Real Chemistry, has joined the board of ICR Inc. as it steps up its healthcare capital markets offering.
Ruder Finn has hired Kelly Yoder, who spent a dozen years at Weber Shandwick rising to North America health lead, as managing director, global head of health & life sciences.
ICR has named John Capodanno head of US healthcare corporate communications and Matthew Willey managing director in its medical technology and diagnostics practice. 
April is National Minority Health Month, spotlighting the urgency to improve health outcomes in communities of color.
In a recent conversation about the evolving media landscape, Doug Simon, CEO of D S Simon Media, spoke with Campbell O’Connor, Group Director, Media & Engagement at Real Chemistry, about how AI is influencing media relations and healthcare communications.
